QM · rank #5 · 2026-09-04
LQDA
NASDAQ · $6.14B (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +344.05% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +131.8% |
| Profit margin Net profit margin, trailing 12 months. | +30.7% |
| Market cap (USD) Size filter: > $500M required. | $6.14B |
| Anchor (recent) Close on 2026-08-05 | $89.12 |
| Anchor (far) Close on 2025-08-05 | $20.07 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Liquidia Technologies is a commercial-stage biopharma generating revenue almost entirely from YUTREPIA, an inhaled dry-powder treprostinil approved for PAH and PH-ILD and built on its proprietary PRINT particle-engineering platform.
Rationale
The quality_momentum signal is reinforced by two consecutive profitable quarters, a 30%+ profit margin, strong ROE, and management characterizing YUTREPIA's launch as one of the top specialty drug launches in recent years — all consistent with a genuine inflection in fundamentals driving price momentum rather than pure sentiment rotation.
Material risks
- 1Single-product concentration means any reimbursement setback, safety signal, or formulary exclusion for YUTREPIA would immediately collapse both revenue and the profitability streak that underpins the quality signal.
- 2Larger PAH incumbents with entrenched nebulized treprostinil franchises and deeper payer relationships could compress YUTREPIA's pricing or access, particularly if payers resist switching patients to a newer inhaled powder format.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.